EGFR and breast carcinoma: Gefitinib was found to bind the ATP pocket of catalytic domain of EGFR kinase, and thus inhibiting the anti-apoptotic signals transduced by mutant EGFR.30 Though there is lack of data of EGFR activating mutations associated with breast cancer, but EGFR overexpression has been reported to occur around 20%–36% breast cancer cases.